Madrigal Pharmaceuticals, Inc. has announced the granting of equity inducement awards to 11 new non-executive employees as part of its 2025 Inducement Plan. The awards were approved on August 15, 2025, and are in line with the company’s efforts to attract talent to support its ongoing research and development initiatives.
The company, which trades on the NASDAQ under the symbol MDGL, issued a total of 6,940 time-based restricted stock units. These units will vest in four equal installments over the first four anniversaries of the grant date. The vesting of these awards is contingent upon the continued employment of each recipient with Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals is focused on developing innovative therapeutics for metabolic dysfunction-associated steatohepatitis, commonly known as MASH. The recent expansion of its workforce reflects the company’s commitment to advancing its research and growth initiatives in this area.
The awards were authorized by the company’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). This rule allows companies to issue inducement grants as part of their recruitment strategies, particularly for new hires who are not yet employees.
Madrigal’s initiative to grant equity awards highlights its strategy to align employee interests with the long-term success of the company. By providing equity as part of compensation, Madrigal aims to foster a sense of ownership among its workforce, which can enhance employee engagement and retention.
As Madrigal Pharmaceuticals continues to grow, it remains focused on its mission to develop effective treatments for MASH, a condition characterized by liver inflammation and damage due to fat accumulation in the liver. The company’s innovative approaches in drug development position it well within the pharmaceutical landscape.
For more updates on Madrigal Pharmaceuticals and developments in the Chester County region, interested parties can follow local news outlets for the latest information.